Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics Inc. (MNPR) is a healthcare company (biotechnology) based in the United States. The share price is $70.85, down 1.56% on the day, which values the company at $480.13M. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$70.85−1.56% today
Market value
$480.13M
200-week average
$33.90109% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Monopar Therapeutics Inc. in more detail

MNPR trades at -25.4× next year's expected earnings. It sits 109% above its 200-week average of $33.90.

In its favour: More cash than debt. Worth checking: Share count keeps rising.

1 of the superinvestors tracked here hold MNPR, including Peter Kolchinsky (0.5% of the portfolio).

Superinvestors holding MNPR

1 of the investors tracked here report a position in their latest 13F filing.

Monopar Therapeutics Inc. (MNPR): questions and answers

What is Monopar Therapeutics Inc.'s market cap?

Monopar Therapeutics Inc. is valued at $480.13M at a share price of $70.85.

Is MNPR above its 200-week moving average?

Yes. MNPR is 109.0% above its 200-week average of $33.90. Long-term investors watch that line because strong companies rarely trade below it for long.

Does MNPR pay a dividend?

Monopar Therapeutics Inc. does not currently pay a regular dividend.

Which famous investors own MNPR?

In their latest quarterly filings, Peter Kolchinsky (0.5% of the portfolio) hold MNPR. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Monopar Therapeutics Inc. (MNPR) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MNPR

Underlying data: Yahoo Finance; company filings with the SEC.